{"id":406358,"date":"2020-12-29T16:57:17","date_gmt":"2020-12-29T21:57:17","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=406358"},"modified":"2020-12-29T16:57:17","modified_gmt":"2020-12-29T21:57:17","slug":"immutep-secures-united-states-patent-for-eftilagimod-alpha-in-combination-with-a-pd-1-pathway-inhibitor","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/immutep-secures-united-states-patent-for-eftilagimod-alpha-in-combination-with-a-pd-1-pathway-inhibitor\/","title":{"rendered":"Immutep Secures United States Patent For Eftilagimod Alpha In Combination With A PD-1 Pathway Inhibitor"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">\n        <strong>Sydney, AUSTRALIA, Dec.  30, 2020  (GLOBE NEWSWIRE) &#8212;  <\/strong><br \/>\n        <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=eLj7FhH6J-xKOaxtB6WzN9KozWKFF88OKTmMBEBneCXqPqMtt9yRTtgWSN4AehSL45T91YZdEugsPBFTFU6_wg==\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">Immutep Limited<\/a> (ASX: IMM; NASDAQ: IMMP) (&#8220;Immutep\u201c or \u201cthe Company\u201c), a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune disease, is pleased to announce the grant of patent number 10,874,713 entitled \u201cCombined Preparations for the Treatment of Cancer or Infection\u201d by the United States Patent &amp; Trade Mark Office.<\/p>\n<p align=\"justify\">This United States patent follows the grant of the corresponding European patent announced in November 2018. The claims of the patent protect Immutep\u2019s intellectual property relating to combined preparations comprising its lead active immunotherapy candidate eftilagimod alpha (\u201cefti\u201d or \u201cIMP321\u201d) and a PD-1 pathway inhibitor. In this case, the PD-1 pathway inhibitor is either pembrolizumab or nivolumab.<\/p>\n<p align=\"justify\">The expiry date of the patent is 8 January 2036.<\/p>\n<p align=\"justify\">This new patent is particularly significant as it covers the combination of active ingredients evaluated in the Company\u2019s phase II TACTI-002 and phase I TACTI-mel trials. It also further highlights the ongoing and important steps being taken by the Company to protect its lead product candidate in a range of novel and commercially relevant combination formats, in both immuno-oncology (IO)-IO and chemo-IO settings.\u00a0<\/p>\n<p align=\"justify\">\u201cWe are very pleased that this United States patent has been granted covering our lead product candidate, efti, in combination with key anti-PD-1 therapies. This is particularly so in view of the highly encouraging data we have seen from both our TACTI (<strong>T<\/strong>wo <strong>Act<\/strong>ive <strong>I<\/strong>mmunotherapies) trials which evaluate efti in combination with pembrolizumab. Furthermore, this new patent and our corresponding patents and patent applications in other key markets continue to underpin our ongoing investment in clinical development\u201d, <strong>said<\/strong><strong>Marc Voigt, CEO of Immutep<\/strong>.<\/p>\n<p align=\"justify\">\n        <strong>Dr. Fr\u00e9d\u00e9ric Triebel, Immutep\u2019s Chief Scientific Officer and Chief Medical Officer<\/strong>, also welcomed the news, noting that, \u201cThis United States patent grant represents another important milestone for the Company, and along with the clinical data we have seen from our trials, supports our long held view that combining efti with an anti-PD-1 checkpoint inhibitor should result in a very meaningful therapeutic benefit to cancer patients.\u201d<\/p>\n<p align=\"justify\">\n        <strong>About Immutep<\/strong><br \/>\n        <br \/>Immutep is a globally active biotechnology company that is a leader in the development of LAG-3 related immunotherapeutic products for the treatment of cancer and autoimmune disease. Immutep is dedicated to leveraging its technology and expertise to bring innovative treatment options to market for patients and to maximize value to shareholders. Immutep is listed on the Australian Securities Exchange (IMM), and on the NASDAQ (IMMP) in the United States.<\/p>\n<p align=\"justify\">Immutep\u2019s current lead product candidate is eftilagimod alpha (\u201cefti\u201d or \u201cIMP321\u201d), a soluble LAG-3 fusion protein (LAG-3Ig), which is a first-in-class antigen presenting cell (APC) activator being explored in cancer and infectious disease. Immutep is also developing an agonist of LAG-3 (IMP761) for autoimmune disease. Additional LAG-3 products, including antibodies for immune response modulation, are being developed by Immutep\u2019s large pharmaceutical partners.<\/p>\n<p align=\"justify\">Further information can be found on the Company\u2019s website <u>www.immutep.com<\/u> or by contacting:<\/p>\n<p align=\"justify\">\n        <strong>Australian Investors\/Media:<\/strong><br \/>\n        <br \/>Catherine Strong, Citadel-MAGNUS<br \/>+61 (0)406 759 268; <u><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=IEw49oa3OCORSOJspfi9mmahaK0NzHh3pMw9U5YGOk9KwU_LtwYuPejnhP5nKCiki6q62tonIcfjNlXC4gQXoEGvcxpVvwfc7beRiDvRstE=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">cstrong@citadelmagnus.com<\/a><\/u><\/p>\n<p align=\"justify\">\n        <strong>U.S. Media:<\/strong><br \/>\n        <br \/>Tim McCarthy, LifeSci Advisors<br \/>+1 (212) 915.2564;\u00a0<u><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=BsYqf5g34E3RmIVLq89zd5wIzdZuYNop5ZFHHcMUBcM29MDG22cYEm8957xymN50fU5LFmINkUwnr5YrU_d1BuUYhvxwgnfmtEh2VAfZG-4=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">tim@lifesciadvisors.com<\/a><\/u><\/p>\n<\/p>\n<p>      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODExODU5OCMzODk5MTQwIzIwMTk4MzM=\" width=\"1\" height=\"1\" \/><br \/>\n      <br \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/ml.globenewswire.com\/release\/track\/a4ee1be4-138f-4ff9-9640-47777eb4c71a\" width=\"1\" height=\"1\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Sydney, AUSTRALIA, Dec. 30, 2020 (GLOBE NEWSWIRE) &#8212; Immutep Limited (ASX: IMM; NASDAQ: IMMP) (&#8220;Immutep\u201c or \u201cthe Company\u201c), a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune disease, is pleased to announce the grant of patent number 10,874,713 entitled \u201cCombined Preparations for the Treatment of Cancer or Infection\u201d by the United States Patent &amp; Trade Mark Office. This United States patent follows the grant of the corresponding European patent announced in November 2018. The claims of the patent protect Immutep\u2019s intellectual property relating to combined preparations comprising its lead active immunotherapy candidate eftilagimod alpha (\u201cefti\u201d or \u201cIMP321\u201d) and a PD-1 pathway inhibitor. In this case, the PD-1 pathway inhibitor is either pembrolizumab or nivolumab. The expiry date of &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/immutep-secures-united-states-patent-for-eftilagimod-alpha-in-combination-with-a-pd-1-pathway-inhibitor\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Immutep Secures United States Patent For Eftilagimod Alpha In Combination With A PD-1 Pathway Inhibitor&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-406358","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Immutep Secures United States Patent For Eftilagimod Alpha In Combination With A PD-1 Pathway Inhibitor - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/immutep-secures-united-states-patent-for-eftilagimod-alpha-in-combination-with-a-pd-1-pathway-inhibitor\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Immutep Secures United States Patent For Eftilagimod Alpha In Combination With A PD-1 Pathway Inhibitor - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Sydney, AUSTRALIA, Dec. 30, 2020 (GLOBE NEWSWIRE) &#8212; Immutep Limited (ASX: IMM; NASDAQ: IMMP) (&#8220;Immutep\u201c or \u201cthe Company\u201c), a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune disease, is pleased to announce the grant of patent number 10,874,713 entitled \u201cCombined Preparations for the Treatment of Cancer or Infection\u201d by the United States Patent &amp; Trade Mark Office. This United States patent follows the grant of the corresponding European patent announced in November 2018. The claims of the patent protect Immutep\u2019s intellectual property relating to combined preparations comprising its lead active immunotherapy candidate eftilagimod alpha (\u201cefti\u201d or \u201cIMP321\u201d) and a PD-1 pathway inhibitor. In this case, the PD-1 pathway inhibitor is either pembrolizumab or nivolumab. The expiry date of &hellip; Continue reading &quot;Immutep Secures United States Patent For Eftilagimod Alpha In Combination With A PD-1 Pathway Inhibitor&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/immutep-secures-united-states-patent-for-eftilagimod-alpha-in-combination-with-a-pd-1-pathway-inhibitor\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2020-12-29T21:57:17+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODExODU5OCMzODk5MTQwIzIwMTk4MzM=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immutep-secures-united-states-patent-for-eftilagimod-alpha-in-combination-with-a-pd-1-pathway-inhibitor\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immutep-secures-united-states-patent-for-eftilagimod-alpha-in-combination-with-a-pd-1-pathway-inhibitor\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Immutep Secures United States Patent For Eftilagimod Alpha In Combination With A PD-1 Pathway Inhibitor\",\"datePublished\":\"2020-12-29T21:57:17+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immutep-secures-united-states-patent-for-eftilagimod-alpha-in-combination-with-a-pd-1-pathway-inhibitor\\\/\"},\"wordCount\":523,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immutep-secures-united-states-patent-for-eftilagimod-alpha-in-combination-with-a-pd-1-pathway-inhibitor\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODExODU5OCMzODk5MTQwIzIwMTk4MzM=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immutep-secures-united-states-patent-for-eftilagimod-alpha-in-combination-with-a-pd-1-pathway-inhibitor\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immutep-secures-united-states-patent-for-eftilagimod-alpha-in-combination-with-a-pd-1-pathway-inhibitor\\\/\",\"name\":\"Immutep Secures United States Patent For Eftilagimod Alpha In Combination With A PD-1 Pathway Inhibitor - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immutep-secures-united-states-patent-for-eftilagimod-alpha-in-combination-with-a-pd-1-pathway-inhibitor\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immutep-secures-united-states-patent-for-eftilagimod-alpha-in-combination-with-a-pd-1-pathway-inhibitor\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODExODU5OCMzODk5MTQwIzIwMTk4MzM=\",\"datePublished\":\"2020-12-29T21:57:17+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immutep-secures-united-states-patent-for-eftilagimod-alpha-in-combination-with-a-pd-1-pathway-inhibitor\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immutep-secures-united-states-patent-for-eftilagimod-alpha-in-combination-with-a-pd-1-pathway-inhibitor\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immutep-secures-united-states-patent-for-eftilagimod-alpha-in-combination-with-a-pd-1-pathway-inhibitor\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODExODU5OCMzODk5MTQwIzIwMTk4MzM=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODExODU5OCMzODk5MTQwIzIwMTk4MzM=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immutep-secures-united-states-patent-for-eftilagimod-alpha-in-combination-with-a-pd-1-pathway-inhibitor\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Immutep Secures United States Patent For Eftilagimod Alpha In Combination With A PD-1 Pathway Inhibitor\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Immutep Secures United States Patent For Eftilagimod Alpha In Combination With A PD-1 Pathway Inhibitor - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/immutep-secures-united-states-patent-for-eftilagimod-alpha-in-combination-with-a-pd-1-pathway-inhibitor\/","og_locale":"en_US","og_type":"article","og_title":"Immutep Secures United States Patent For Eftilagimod Alpha In Combination With A PD-1 Pathway Inhibitor - Market Newsdesk","og_description":"Sydney, AUSTRALIA, Dec. 30, 2020 (GLOBE NEWSWIRE) &#8212; Immutep Limited (ASX: IMM; NASDAQ: IMMP) (&#8220;Immutep\u201c or \u201cthe Company\u201c), a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune disease, is pleased to announce the grant of patent number 10,874,713 entitled \u201cCombined Preparations for the Treatment of Cancer or Infection\u201d by the United States Patent &amp; Trade Mark Office. This United States patent follows the grant of the corresponding European patent announced in November 2018. The claims of the patent protect Immutep\u2019s intellectual property relating to combined preparations comprising its lead active immunotherapy candidate eftilagimod alpha (\u201cefti\u201d or \u201cIMP321\u201d) and a PD-1 pathway inhibitor. In this case, the PD-1 pathway inhibitor is either pembrolizumab or nivolumab. The expiry date of &hellip; Continue reading \"Immutep Secures United States Patent For Eftilagimod Alpha In Combination With A PD-1 Pathway Inhibitor\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/immutep-secures-united-states-patent-for-eftilagimod-alpha-in-combination-with-a-pd-1-pathway-inhibitor\/","og_site_name":"Market Newsdesk","article_published_time":"2020-12-29T21:57:17+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODExODU5OCMzODk5MTQwIzIwMTk4MzM=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immutep-secures-united-states-patent-for-eftilagimod-alpha-in-combination-with-a-pd-1-pathway-inhibitor\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immutep-secures-united-states-patent-for-eftilagimod-alpha-in-combination-with-a-pd-1-pathway-inhibitor\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Immutep Secures United States Patent For Eftilagimod Alpha In Combination With A PD-1 Pathway Inhibitor","datePublished":"2020-12-29T21:57:17+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immutep-secures-united-states-patent-for-eftilagimod-alpha-in-combination-with-a-pd-1-pathway-inhibitor\/"},"wordCount":523,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immutep-secures-united-states-patent-for-eftilagimod-alpha-in-combination-with-a-pd-1-pathway-inhibitor\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODExODU5OCMzODk5MTQwIzIwMTk4MzM=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immutep-secures-united-states-patent-for-eftilagimod-alpha-in-combination-with-a-pd-1-pathway-inhibitor\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/immutep-secures-united-states-patent-for-eftilagimod-alpha-in-combination-with-a-pd-1-pathway-inhibitor\/","name":"Immutep Secures United States Patent For Eftilagimod Alpha In Combination With A PD-1 Pathway Inhibitor - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immutep-secures-united-states-patent-for-eftilagimod-alpha-in-combination-with-a-pd-1-pathway-inhibitor\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immutep-secures-united-states-patent-for-eftilagimod-alpha-in-combination-with-a-pd-1-pathway-inhibitor\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODExODU5OCMzODk5MTQwIzIwMTk4MzM=","datePublished":"2020-12-29T21:57:17+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immutep-secures-united-states-patent-for-eftilagimod-alpha-in-combination-with-a-pd-1-pathway-inhibitor\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/immutep-secures-united-states-patent-for-eftilagimod-alpha-in-combination-with-a-pd-1-pathway-inhibitor\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immutep-secures-united-states-patent-for-eftilagimod-alpha-in-combination-with-a-pd-1-pathway-inhibitor\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODExODU5OCMzODk5MTQwIzIwMTk4MzM=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODExODU5OCMzODk5MTQwIzIwMTk4MzM="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immutep-secures-united-states-patent-for-eftilagimod-alpha-in-combination-with-a-pd-1-pathway-inhibitor\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Immutep Secures United States Patent For Eftilagimod Alpha In Combination With A PD-1 Pathway Inhibitor"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/406358","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=406358"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/406358\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=406358"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=406358"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=406358"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}